ClinicalTrials.gg
CompletedNCT03776968Updated Oct 23, 2024

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

A Phase 1 interventional study of HC1119 in Metastatic Castration Resistant Prostate Cancer, sponsored by Hinova Pharmaceuticals Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Hinova Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2017, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
70th of 125
47 · median 52
Started
2017
with 10 others
Phase 1
22 of 125
2 open now
Registered
87th of 125
by date
Lead sponsor
3 of 125
Hinova Pharmaceuticals Inc.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 70th largest by enrollment, is one of 11 that started in 2017, is one of 22 in phase 1, and was the 87th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults. The study primary objective is to evaluate the HC-1119 pharmacokinetic characteristics and the effect of food on its pharmacokinetics in healthy Chinese males, subsequent to a single oral administration of HC-1119 with different doses in healthy Chinese males.

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed the form.
  2. Healthy Chinese male aged between 18-45 years old (inclusive).
  3. Weight ≥ 50.0 kg, and between 19.0-26.0 kg/m2 (inclusive) at screening. BMI = weight (kg) / height2 (m2).
  4. Defined as "healthy" based on past medical history, physical examination, vital signs, laboratory tests, 12-Lead , and chest x-ray performed at screening. All examination results must be within the normal range corresponding to the subject's age and gender, or determined by the investigator as "no clinical significance (NCS)" when the result is out of range.
  5. All male subjects and their female spouses/sexual partners with must adopt continuous and effective methods, that is, two forms of contraception should be performed spontaneously (including at least one barrier method), from the initiation of screening and the whole study period to at least three months after administration.
  6. Able to maintain a consistency of good communication with the investigators, and understand and comply with all the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. A history of cardiovascular, lung, hepatic, renal, respiratory, nervous system, musculoskeletal, endocrine, or GI disease, or a history of other serious systemic diseases.
  2. A history of drug allergies or a history of specific allergic disease (asthma, urticaria, eczema dermatitis), especially being allergic to any ingredients of the study drug or formulation.
  3. Suffered (within 1 week prior to the study) or currently suffering from febrile illness, symptomatic viral infection, bacterial infection (including upper respiratory tract infection), or fungal infection (except skin infection).
  4. Administered any prescription drugs, Chinese herbal medicine, OTC drugs, or food supplements (including vitamins) within 4 weeks prior to the study.
  5. Administered any inducers or inhibitors of hepatic drug metabolism within 1 month prior to the study (such as: inducers - barbiturates, carbamazepine, phenytoin, , and omeprazole; inhibitors - antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, and antihistamines).
  6. History of seizures within 12 months prior to the study, including any history of febrile seizures, loss of consciousness, or , and any condition that increases the risk of seizures (such as history of stroke, cerebral arteriovenous malformation, traumatic brain injury with coma requiring hospitalization, and lacunar infarct).
  7. Recent history (in the past 3 years) and/or current medical history of autonomic dysfunction (such as recurrent syncope and palpitations).
  8. History of medication abuse or a positive urine drug screen within 12 months prior to the study.
  9. Smokers or those who smoked more than 10 cigarettes per day (or equivalent amounts of tobacco) within 3 months prior to the study, or those who are unable to stop smoking during the entire course of the study.
  10. History of alcohol abuse or those with regular consumption of alcoholic beverages (daily consumption exceeding 14 units of alcohol, 1 unit = 360 ml of beer, 45 ml of 40% liquor, or 150 ml of wine) within 6 months prior to the study, or having a positive breath alcohol test result.
  11. Donated or lost blood ≥ 400 ml of blood within 3 months prior to the study.
  12. Received treatment with any drug or participated in any clinical trial within 3 months prior to the study.
  13. Requiring a special diet and unable to follow a standardized diet.
  14. Overconsumption of tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 ml).
  15. Consumed grapefruit or product containing grapefruit (such as jam) within 1 week prior to receiving the investigational drug.
  16. Positive , , , or syphilis test result.
  17. Cannot complete this study for any other reasons, or determined by the investigator to be unsuitable for this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    HC1119

    Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;

    Drug: HC1119

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)

    Time frame: From the first dose of the study drug to day 50

  2. Area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration(AUC0-t)

    Time frame: From the first dose of the study drug to day 50

  3. Peak concentration (Cmax)

    Time frame: From the first dose of the study drug to day 50

  4. Peak time (Tmax)

    Time frame: From the first dose of the study drug to day 50

  5. Elimination half life (t1/2)

    Time frame: From the first dose of the study drug to day 50

  6. Apparent clearance (CL/F) (prototype)

    Time frame: From the first dose of the study drug to day 50

  7. Apparent volume of distribution (Vd/F) (prototype)

    Time frame: From the first dose of the study drug to day 50

  8. Mean residence time (MRT)

    Time frame: From the first dose of the study drug to day 50

Secondary outcomes

  1. Number of patients with adverse events

    Safety measures

    Time frame: From the first dose of the study drug to day 50

07

Study locations

1 site
  • Shanghai Changhai Hospital Ethics Committee
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jan 2018, 2 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 2 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 17, 2018
StartActual
Oct 24, 2017
Primary completionActual
Jan 15, 2018
CompletionActual
Jul 3, 2018
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03776968
Lead sponsor
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Oct 24, 2017
Primary completion
Jan 15, 2018
Completion
Jul 3, 2018
Last update
Oct 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion